UY33206A - Métodos de tratamiento de enfermedades autoinmunes con antagonistas de dll4 - Google Patents

Métodos de tratamiento de enfermedades autoinmunes con antagonistas de dll4

Info

Publication number
UY33206A
UY33206A UY0001033206A UY33206A UY33206A UY 33206 A UY33206 A UY 33206A UY 0001033206 A UY0001033206 A UY 0001033206A UY 33206 A UY33206 A UY 33206A UY 33206 A UY33206 A UY 33206A
Authority
UY
Uruguay
Prior art keywords
methods
autoimmune diseases
diseases
treatment
disease
Prior art date
Application number
UY0001033206A
Other languages
English (en)
Inventor
Skokos Dimitris
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of UY33206A publication Critical patent/UY33206A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Esta invención proporciona métodos de tratamiento de una enfermedad en los que es beneficioso incrementar el número de células T regulatorias (Treg). administrando a un sujeto que padece dicha enfermedad una cantidad terapeúticamente eficaz de antagonistas de DII4 que bloquean la rutas de señalización DII4-Notch, por lo que se incrementa el númeto de Treg. Las enfermedades o los trastornos tratables mediante los métodos de la invención incluyen las enfermedades o trastornos autoinmunes, tales como esclerosis múltiple (MS), diabetes, y similares. La invención también permite prevenir la aparición de tales enfermedades, y prevenir o tratar los rechazos de trasplantes.
UY0001033206A 2010-01-29 2011-01-28 Métodos de tratamiento de enfermedades autoinmunes con antagonistas de dll4 UY33206A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29980110P 2010-01-29 2010-01-29
US36168710P 2010-07-06 2010-07-06
US38869710P 2010-10-01 2010-10-01

Publications (1)

Publication Number Publication Date
UY33206A true UY33206A (es) 2011-08-31

Family

ID=43925413

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001033206A UY33206A (es) 2010-01-29 2011-01-28 Métodos de tratamiento de enfermedades autoinmunes con antagonistas de dll4

Country Status (29)

Country Link
US (3) US8765125B2 (es)
EP (2) EP2528945B1 (es)
JP (2) JP5883801B2 (es)
KR (2) KR101797918B1 (es)
CN (2) CN102947336B (es)
AR (1) AR080026A1 (es)
AU (2) AU2011210773B2 (es)
BR (2) BR112012018820A8 (es)
CA (2) CA2787394C (es)
CY (2) CY1118223T1 (es)
DK (2) DK2528946T3 (es)
ES (2) ES2605430T3 (es)
HR (2) HRP20170130T1 (es)
HU (2) HUE031432T2 (es)
IL (2) IL220889A (es)
JO (2) JO3183B1 (es)
LT (2) LT2528945T (es)
MX (2) MX343555B (es)
MY (2) MY156353A (es)
PL (2) PL2528945T3 (es)
PT (2) PT2528946T (es)
RS (2) RS55595B1 (es)
RU (2) RU2587620C2 (es)
SG (4) SG182527A1 (es)
SI (2) SI2528946T1 (es)
SM (2) SMT201600412B (es)
TW (2) TWI564019B (es)
UY (1) UY33206A (es)
WO (2) WO2011094467A2 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2448979C2 (ru) 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Антитела человека к дельта-подобному лиганду-4 человека
JP5903382B2 (ja) 2009-08-29 2016-04-13 アッヴィ・インコーポレイテッド 治療用ｄｌｌ４結合タンパク質
US8883145B2 (en) 2009-10-16 2014-11-11 Oncomed Pharmaceuticals, Inc. Methods of treatment with DLL4 antagonists and an anti-hypertensive agent
JO3183B1 (ar) 2010-01-29 2018-03-08 Regeneron Pharma طرق لمعالجة أمراض المناعة الذاتية مضادات dll4
CN105037543B (zh) 2010-03-02 2020-11-03 Abbvie 公司 治疗性dll4结合蛋白
US8858941B2 (en) 2011-09-23 2014-10-14 Oncomed Pharmaceuticals, Inc. VEGF/DLL4 binding agents and uses thereof
KR101535341B1 (ko) * 2012-07-02 2015-07-13 한화케미칼 주식회사 Dll4에 특이적으로 결합하는 신규한 단일클론항체 및 이의 용도
CN104884472B (zh) 2012-11-01 2021-10-15 艾伯维公司 抗-vegf/dll4双重可变结构域免疫球蛋白及其用途
AR093445A1 (es) * 2012-11-14 2015-06-10 Regeneron Pharma Metodos para tratar el cancer de ovario con antagonistas de dll4
RU2648154C2 (ru) 2013-07-09 2018-03-22 Аблбио Новые белки, специфично связывающиеся с двумя мишенями -dll4 и vegf-, и их применение
CN111239415B (zh) * 2013-10-17 2024-03-26 综合医院公司 鉴定响应于用于自身免疫性疾病的治疗的受试者的方法以及用于治疗该疾病的组合物
CA2944811C (en) * 2014-04-08 2022-06-21 Urs Christen Combination therapy for the treatment of autoimmune diseases
WO2016070051A2 (en) 2014-10-31 2016-05-06 Oncomed Pharmaceuticals, Inc. Combination therapy for treatment of disease
CN109071644B (zh) 2015-09-23 2023-09-19 昂考梅德药品有限公司 治疗癌症的方法和组合物
WO2020113099A1 (en) * 2018-11-29 2020-06-04 Gary Aaron Howard Method for treating or preventing seizures associated with an epileptic disorder
US11446262B2 (en) 2018-11-29 2022-09-20 Debora Zucco Sassi Yonezawa Siviglia Neuroquiescence—a treatment for neurodevelopmental and neurodegenerative bioelectrical dysregulation and demyelination
JPWO2022210802A1 (es) * 2021-03-30 2022-10-06
WO2023159166A1 (en) * 2022-02-18 2023-08-24 H. Lee Moffitt Cancer Center And Research Institute, Inc. Single-domain antibodies (nanobodies) targeting the notch ligand dll4 and methods of their use

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6927044B2 (en) 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
US7138370B2 (en) 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
EP1505977B1 (en) * 2002-05-21 2014-09-10 Gilead Sciences, Inc. Administration of a partial fatty acid oxidation inhibitor such as ranolazine for the treatment of diabetes
US7850962B2 (en) 2004-04-20 2010-12-14 Genmab A/S Human monoclonal antibodies against CD20
US20060134121A1 (en) * 2004-10-29 2006-06-22 Gavin Thurston DII4 antagonists, assays, and therapeutic methods thereof
PL1962895T3 (pl) 2005-12-16 2013-06-28 Regeneron Pharma Terapeutyczne zastosowanie antagonisty dii4 oraz inhibitora vegf do inhibicji wzrostu nowotworów
DK2374818T3 (da) 2006-06-02 2013-01-21 Regeneron Pharma Højaffinitetsantistoffer mod human IL-6-receptor
WO2008060705A2 (en) * 2006-06-06 2008-05-22 Genentech, Inc. Anti-dll4 antibodies and methods using same
RU2008152435A (ru) 2006-06-06 2010-07-20 Дженентек, Инк. (Us) Композиции и способы регулирования развития сосудов
BRPI0716424B8 (pt) 2006-08-07 2021-05-25 Regeneron Pharma uso do antagonista de ligante delta-like 4 (dll4)
EA018260B1 (ru) 2006-09-29 2013-06-28 Онкомед Фармасьютикалз, Инк. Антитела к дельта-подобному лиганду 4 человека и их применение
RU2448979C2 (ru) * 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Антитела человека к дельта-подобному лиганду-4 человека
JP5903382B2 (ja) * 2009-08-29 2016-04-13 アッヴィ・インコーポレイテッド 治療用ｄｌｌ４結合タンパク質
JO3183B1 (ar) 2010-01-29 2018-03-08 Regeneron Pharma طرق لمعالجة أمراض المناعة الذاتية مضادات dll4

Also Published As

Publication number Publication date
CY1118223T1 (el) 2017-06-28
BR112012018820A2 (pt) 2017-01-10
HRP20170130T1 (hr) 2017-03-24
SG182527A1 (en) 2012-08-30
PL2528946T3 (pl) 2017-04-28
DK2528946T3 (en) 2017-02-20
EP2528945A2 (en) 2012-12-05
US20140255429A1 (en) 2014-09-11
CN102947336A (zh) 2013-02-27
CA2787394C (en) 2019-01-08
RU2587620C2 (ru) 2016-06-20
HUE031432T2 (en) 2017-07-28
AU2011210771A1 (en) 2012-08-23
MY156353A (en) 2016-02-15
JP2013518123A (ja) 2013-05-20
CN102884081A (zh) 2013-01-16
CY1118551T1 (el) 2017-07-12
WO2011094467A3 (en) 2011-12-22
RU2012136816A (ru) 2014-03-10
WO2011094467A2 (en) 2011-08-04
JP5883801B2 (ja) 2016-03-15
EP2528946B1 (en) 2016-11-16
SG10201500404QA (en) 2015-03-30
MX343553B (es) 2016-11-10
RU2587624C2 (ru) 2016-06-20
KR20130008017A (ko) 2013-01-21
CA2787394A1 (en) 2011-08-04
JP2013518122A (ja) 2013-05-20
TWI600433B (zh) 2017-10-01
ES2609663T3 (es) 2017-04-21
RU2012136817A (ru) 2014-03-10
BR112012018820A8 (pt) 2018-03-13
SG10201500416RA (en) 2015-04-29
IL220889A (en) 2017-07-31
KR20120123745A (ko) 2012-11-09
JO3183B1 (ar) 2018-03-08
ES2605430T3 (es) 2017-03-14
US8765125B2 (en) 2014-07-01
KR101797918B1 (ko) 2017-11-15
WO2011094465A4 (en) 2011-09-22
JP5997613B2 (ja) 2016-09-28
MX2012008638A (es) 2012-12-05
PL2528945T3 (pl) 2017-02-28
SI2528945T1 (sl) 2017-01-31
DK2528945T3 (en) 2017-02-06
SG182528A1 (en) 2012-08-30
MX343555B (es) 2016-11-10
SMT201600412B (it) 2017-01-10
EP2528946A1 (en) 2012-12-05
US20110189176A1 (en) 2011-08-04
CA2787615C (en) 2019-01-15
HUE032985T2 (en) 2017-11-28
LT2528945T (lt) 2017-01-25
MX2012008740A (es) 2012-08-31
PT2528945T (pt) 2016-12-14
SMT201700021B (it) 2017-03-08
EP2528945B1 (en) 2016-10-26
LT2528946T (lt) 2017-01-25
SI2528946T1 (sl) 2017-01-31
AU2011210773A1 (en) 2012-08-23
TW201615207A (zh) 2016-05-01
RS55595B1 (sr) 2017-06-30
CN102947336B (zh) 2015-12-02
BR112012018766A2 (pt) 2017-01-10
KR101832118B1 (ko) 2018-02-26
US8889133B2 (en) 2014-11-18
TWI564019B (zh) 2017-01-01
HRP20170249T1 (hr) 2017-04-07
RS55715B1 (sr) 2017-07-31
JO3242B1 (ar) 2018-03-08
CA2787615A1 (en) 2011-08-04
AU2011210773B2 (en) 2015-11-19
WO2011094465A1 (en) 2011-08-04
MY156538A (en) 2016-02-26
AU2011210771B2 (en) 2015-12-10
US20110189200A1 (en) 2011-08-04
IL220887A (en) 2017-07-31
PT2528946T (pt) 2016-12-14
AR080026A1 (es) 2012-03-07
IL220889A0 (en) 2012-09-24
TW201136601A (en) 2011-11-01

Similar Documents

Publication Publication Date Title
UY33206A (es) Métodos de tratamiento de enfermedades autoinmunes con antagonistas de dll4
UY32968A (es) Compuestos heterocíclicos fusionados como moduladores del receptor de orexina
UY32967A (es) Compuestos heterocíclicos fusionados como moduladores del receptor de la orexina
BR112016011483A2 (pt) Derivados de imidazotriazina como moduladores de atividade de tnf
UY32966A (es) Octahidropirrolo (3,4-c) pirroles disustituidos como moduladores del receptor de orexina
PE20150631A1 (es) Formas cristalinas de un modulador del receptor androgenico
GT201300209A (es) Compuestos y composiciones como inhibidores de la trk
IN2014DN00288A (es)
IN2014MN00093A (es)
BR112016011485A2 (pt) Derivados de imidazopiridazina como moduladores de atividade de tnf
BRPI0808775A2 (pt) compostos e composições como moduladores de atividade de gpr119
ECSP14000357A (es) Derivados de 8-carbamoil-2-(2,3- pirid- 6- ilo di sustituido) -1,2,3,4 -tetrahidroisoquinolina como agentes inductores de la apoptosis para el tratamiento del cancer y enfermedades inmunes y autoinmunes
CL2013001247A1 (es) Metodo de tratamiento y/o prevencion del estres oxidativo, estres vascular y/o disfuncion endotelial en pacientes no diabeticos o en pacientes con diabetes tales como de tipo 1, diabetes autoinmune latente del adulto (dala) y diabetes de tipo 2, que comprende administrar linagliptina; compuesto linagliptina, inhibidor de dpp-4.
IN2014MN01378A (es)
GT201400191A (es) Esketamina para el tratamiento de la depresión refractaria al tratamiento o resistente al tratamiento
NI201200029A (es) Compuestos y composiciones como inhibidores de cinasa de proteína
EA201891833A1 (ru) Комбинация для лечения амиотрофического бокового склероза или родственных болезней
EA201390060A1 (ru) Аннелированные пиримидины и триазины и их применение для лечения и/или профилактики сердечно-сосудистых заболеваний
EA200901032A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
ECSP14010817A (es) Composición y método para el diagnóstico y el tratamiento de las enfermedades asociadas a la degeneración de las neuritas
EA201100138A1 (ru) 4-феноксиметилпиперидины в качестве модуляторов активности gpr119
WO2012149478A3 (en) Agents useful for treating friedreich's ataxia and other neurodegenerative diseases
CR20130464A (es) Inhibidores sustituidos de acetil-coa carboxilasa
UY32937A (es) Compuestos y composiciones como moduladores de la actividad de gpr119
EA201390506A1 (ru) Полипептиды, которые связывают компонент с5 комплемента человека

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20191209